The provision of HIV medications to HIV-negative persons after exposure to HIV is known as postexposure prophylaxis (PEP). Because this prevention strategy is primarily only available in emergency rooms, we piloted a nurse-led communitybased PEP program in Ottawa from September 2013 through August 2015. As part of evaluating this program, we conducted qualitative interviews with persons who initiated PEP. Twelve men who had engaged in condomless anal sex with other males participated. Thematic analysis of the interview transcripts highlighted that PEP was considered unmentionable because the participants' saw it as proof of past behavior that was perceived negatively. Our results thus revealed that PEP was stigmatized, which made our participants reluctant to answer health care professionals' ''questions'' about why they needed PEP. To do so was to be exposed to stigma. The use of PEP for our participants was a balance between wanting to minimize the risks of HIV acquisition against the risks of disclosing the unmentionable. We take these findings to mean that clinicians and health service policy workers should move PEP into community clinics (decentralizing it from hospitals, and increase the involvement of nurses); aim to provide all required PEP services in community settings (consolidate PEP provision in these clinics); and ensure PEP services are streamlined to remove extraneous data collection (meaning history and exam tools should be standardized to minimize needless questions that may impede PEP access). Together, these recommendations may increase patients' access to PEP, and maximize its HIV prevention effects.
In Canada, HIV mainly affects men who have sex with men and persons who use injection drugs (Public Health Agency of Canada, 2011) . Despite decreases in the number of HIV diagnoses in Canada during the 1990s, over the last 10 years, rates have risen or remained stable, signaling the need for renewed prevention efforts. One strategy is HIV postexposure prophylaxis (PEP), which is the provision of HIV medications to HIV-negative persons after exposure to HIV (Tan et al., 2017) . Animal studies demonstrate the utility of PEP when used within 72 hour postexposure and continued for 28 days (Bourry et al., 2009; Otten et al., 2000) . Cardo et al.'s (1997) case-control study among health care staff (primarily nurses) also identified an 81% reduction in HIV acquisition, demonstrating its effectiveness among humans. In combination with animal model data, this study made PEP standard-of-care in most emergency rooms, wherein physicians assess patients and prescribe PEP as indicated (Centers of Disease Control [CDC], 2016; Tan et al., 2017) . Despite PEP's effectiveness, barriers to its usage are people's lack of awareness and a reluctance to access it (de Silva, Miller, & Walsh, 2006; Mehta et al., 2011) .
To increase access to PEP, we established a nurse-led PEP pilot program in two HIV testing clinics in Ottawa, Ontario, Canada (O 'Byrne, Roy, & Kitson, 2016) . To evaluate the program, we interviewed patients who initiated PEP, with the goal of using their perceptions and insights to better understand PEP use and to improve subsequent service delivery. We identified that PEP was what we entitled, ''unmentionable.'' This result is unique, in that our previous findings described our participants' perceptions of risk and how PEP functions within their HIV prevention strategies (O 'Byrne, Orser, MacPherson, & Valela, 2018) . In this article, we contextualize PEP and provide a description of the study and its findings. We conclude with a discussion of the study's limitations and the implications of our research for practice, research, and policy.
Background

Situating the Project
In Canada, access to HIV care is broken into diagnostic and treatment services. Diagnostic services are available irrespective of insurance in primary and specialist settings (both requiring insurance) and in public testing centers (not requiring insurance). Often, baccalaureate prepared nurses staff the public clinics and perform testing under medical directives. For HIV treatment, health insurance is required, which is commonly provided by the single-payer systems available to Canadian residents. In this project, the Ontario Health Insurance Plan (OHIP) paid for HIV testing, but did not cover medication. Outside of primary series vaccinations and certain communicable disease medications (e.g., for chlamydia), medications and other treatments are purchased through private insurance or a public insurance plan, with the latter only covering some persons; for example, people less than 25 or greater than 65 years of age, or those of low socioeconomic status. There is also a provincial sliding scale drug program, which offsets medication costs based on a person's annual income. Baring access to these programs, medications-including PEP-must be purchased with private insurance or out-of-pocket funds. For this pilot, each 28 days of PEP cost $1,732 (Canadian dollars).
Project Aims
The research study addressed two questions: (a) What are the clinical and patient satisfaction outcomes associated with providing free PEP medication? and (b) What are the outcomes associated with nurses delivering PEP?
Our aim was to determine the costs and HIV prevention outcomes of providing free PEP in the context of a single-payer insurance system, that is, OHIP (Ontario Health Insurance Plan). We also sought to evaluate the aforementioned outcomes associated with having nurses provide PEP in community clinical settings. Such evidence could add to the literature, which often included people who could afford PEP and services provided by physicians (not nurses working under medical directives) in emergency room settings.
Project Overview
Our pilot provided patients with community-based access to PEP after HIV exposure. Trained nurses determined patient eligibility for PEP based on if (a) the HIV exposure occurring less than 72 hr from when an HIVnegative patient presented to clinic for PEP, (b) the acts the patient engaged in posed a risk for HIV transmission, and (c) the sexual or injection drug sharing partner was HIV-positive or of unknown HIV status (O 'Byrne et al., 2016) . Unknown HIV status was included for these groups because, in Ottawa, they have an estimated HIV prevalence of 11%, compared with 0.3% among the entire population (Friedman, O'Byrne, & Roy, 2017; Public Health Agency of Canada, 2011) . If these three criteria were met, nurses provided the patient with PEP medications immediately. Eight nurses were trained for PEP assessment and initiation. These nurses read extant guidelines, undertook a training session with the principal investigator (O'Byrne), completed a written test, and were observed once assessing for and providing PEP in clinical practice.
Methods
Research Ethics Boards at the University of Ottawa, Ottawa Public Health, and the Ottawa Hospital Research Institute approved this project in 2013.
Design
We conducted a mixed methods observational field test with nested qualitative interviews. The observational data collection outcomes have been published elsewhere (O 'Byrne, MacPherson, & Orser, 2018; O'Byrne, MacPherson, Roy, Orser, 2017) . The qualitative study design was a modified form of grounded theory, wherein we used exploratory thematic analysis to filter the interview transcript data without a preestablished coding schema. We refer to this approach as modified because we were not naı¨ve to the topics of PEP, HIV transmission, HIV prevention, and risk, and went into the interviews with previous knowledge and understanding, although not a priori generated codes or themes.
Sampling
Because the objective of the qualitative component of this study was to describe participants' rationales for and experiences of using PEP, the pool of potential participants for qualitative inquiry comprised only those who initiated PEP through our study, which ran from September 2013 through August 2015. If patients requested PEP and signed the study consent form for the clinical intervention, the clinical PEP nurse asked them if the research team could contact them within 6 months of completing PEP to discuss being interviewed for the study. The PEP study consent form contained information about the use, risks, and benefits of PEP, and our clinical data tracking. It also had a box for patients to indicate how, if at all, they were willing to participate in the study. The options were (a) obtain PEP but decline all study participation, (b) obtain PEP and participate in clinical data tracking but decline the invitation to discuss an interview, and (c) obtain PEP, participate in the clinical data tracking, and accept the invitation to discuss the interview. Those who agreed to discuss an interview were contacted by phone, and asked if they were still interested in participating. If the potential participant agreed, we arranged an interview at one of our two clinics (the Sexual Health Clinic or GayZone) or at the University of Ottawa in the principal investigator's office.
Data Collection
The project's research assistant (an HIV community activist) conducted face-to-face, one-on-one, audio-recorded interviews. The interviews were semistructured, meaning that each one was based on prompts we developed from a review of the literature and our clinical and research experience (see Table 1 ). The interview was not limited to these prompts, but allowed participants to raise points we had not identified. After each interview, the research assistant transcribed the audio recording verbatim.
Data Analysis
We analyzed the data using the principles of thematic discourse analysis, with its aims of ''identifying and describing both implicit and explicit ideas within the data'' (Guest, MacQueen, & Namey, 2012, p. 10) . This involved (a) multiple line-by-line readings of the text, (b) segmentation of the text to identify ideas and concepts, (c) coding of these segments, (d) clustering of codes based on them having similar content, (e) grouping of similar clusters to produce larger aggregates, (f) labelling aggregates, and (g) producing a narrative that explained the findings (Guest et al., 2012; Kelly, 2010) . We undertook steps (a) through (c) independently, and compared our codes for consistency. Where discrepancy arose, we returned to the raw interview data for discussion. The outcome was acceptance of one code over another or a recognition that both points were valid and needed inclusion. We undertook steps (d) through (g) collectively.
Findings
Of the patients who initiated PEP through our program (n ¼ 72), 12 were interviewed (16.7% participation rate).
These 12 participants were all HIV-negative males who sought PEP after condomless anal sex with men. Two of these participants had used PEP before; none had used preexposure prophylaxis (PrEP). Follow-up HIV testing at 6 weeks post-PEP was negative for all interview participants, although we diagnosed one participant with HIV 12 months after completing PEP, likely due to a subsequent exposure (not a PEP failure).
Analysis of the interview transcripts identified the following overarching narrative: PEP is unmentionable, with three dimensions: (a) PEP is stigmatized because it is seen as the outcome of poor judgment, (b) the result of PEP stigma is active nondisclosure related to PEP, and (c) the sexual contacts that led to PEP may recur.
PEP as Unmentionable
The overarching narrative in the interviews was that PEP was something not to be disclosed. Although none of the participants used the word ''unmentionable,'' its definition captured their sentiments that PEP was ''too embarrassing, offensive, or shocking to be spoken about'' (New Oxford American dictionary, 2013). Inherent in this definition was the participants' perspectives that, although they had engaged in sexual activities that warranted PEP, they felt it was inappropriate to discuss these practices. In our results, this distinction highlighted that the participants were not concerned about their sexual practices per se, but the disclosure of these practices. We next elaborate on three dimensions of this finding.
Dimension 1: PEP as the Sign of Stigma
Among our participants, the notion that PEP was unmentionable was rooted in the belief that PEP was associated with negative attributes and status loss. That is, PEP was stigmatizing because it was seen as a manifestation of ''poor'' judgment. One participant stated, ''I know people know about PEP and PrEP [preexposure prophylaxis], but I don't know anyone who uses it. It's taboo'' (Int 6).
In this quote, the important point is the negative association attributed to PEP-seeing it as ''taboo.'' That is, for this participant, PEP holds a negative connotation and is taboo, defined as something ''prohibited or restricted by social custom'' (New Oxford American dictionary, 2013). Another participant echoed this perception when we asked him if he discussed his PEP treatment with friends: ''Not really . . . . I just think it is none of their business, and maybe a bit of shame. I wouldn't say shame. I would say afraid of being judged'' (Int 3).
As this participant described, the stigma surrounding PEP drew associations between its use and judgment from others. Another participant noted that PEP could be seen as proof of ''risky'' choices. For example, when asked about others' assumptions about him if they learned about his PEP use, he said, ''I think a lot of people would say, 'well, they went on this HIV exposure medication, obviously it is through a sexual practice.''' When asked if that is something that could be negative, he answered, ''Yeah . . . . Somebody who had that information would go, 'This person is putting himself at risk''' (Int 2).
Expressed here is a belief that PEP is not just a prevention intervention; it is evidence that a person engaged in practices that put him ''at risk'' for HIV acquisition, which this participant felt implied he had poor decisions and lack of judgment. The next participant explained how such negative attributes could lead to discrediting social interactions, such as during a previous health care assessment for PEP at the emergency room: ''I had to get a lecture from a nurse who said, 'Why were you there [bathhouse] in the first place? You shouldn't be going to those places. It's very risky''' (Int 1).
Here, the assumption of risk avoidance is clear: The participant reported a story about how a nurse had chastised him for attending a bathhouse, rather than remaining neutral or commending his decision to seek PEP. Another participant further explained the relationship between PEP, stigma, and condomless sex:
There is certainly a stigma attached to bareback sex that it is dirty and bad . . . and this all has to do with HIV . . . . Even though I do feel guilty, I refuse to be put under the blanket understanding of the stigma that it is bad and wrong. (Int 6) The assumption here is that PEP is unmentionable due to the participant's perceptions about its negative social assumptions about ''why'' people use it: PEP is needed after condomless sex, which is seen as ''dirty and bad'' due to HIV transmission, and, as such, is constructed as evidence that a person engaged in a stigmatized practice.
Continuing this association between PEP and HIV stigma, another participant reported concerns about HIV-status assumption: ''I didn't want them to start saying, 'oh,' thinking I was HIV-positive'' (Int 3). In this case, worries about PEP were such that, in using HIV medications for prevention, others might have thought that he was HIV-positive, which he wanted to avoid.
Another aspect of HIV stigma and PEP that other participants recounted was that the very act of attending clinics where PEP is available could bestow stigma. In describing his experience accessing our program, a participant stated:
I think it was more awkward . . . . It is easier to go to just one person, rather than this walk-in clinic. Who knows who you are going to see . . . . It's uncomfortable, especially if you go into the clinic and you run into people you know, because you're being judged. (Int 5) I think I would be more comfortable going to a place that has the word ''gay'' in it, instead of coming here, where you've got drug addicts, prostitutes. (Int 11) For these participants, the stigma attached to PEP included the activity of going to the clinic where PEP is offered. For our participants, this association was based on the assumption that simply presenting to such settings could lead others to make incorrect judgments about them.
Dimension 2: Active Nondisclosure
The second dimension of PEP's unmentionability related to the participants' comments that they did not wish to verbalize their need for and use of PEP to others to the point that PEP was not just private, but something to keep secret. Specifically, our participants reported that they did not disclose their PEP use to peers, and only reluctantly did so to clinicians, usually because they perceived that others would perceive their PEP use as proof of risk-taking. Indeed, although some participants reported not having problems informing friends about PEP, most were reluctant to do so:
I'll talk about my sex life with really close friends but when it comes to something like, I put myself in a situation where I had been exposed [to HIV] and I am on this medication, there's probably only one friend I would talk to about it. But I didn't. (Int 2) Here, the participant indicated that although he openly discusses his sex life with some close friends, he did not disclose his PEP use even to the one close friend he might have confided in. Another participant made a similar point: ''I was hiding it from my friends. I told you I told some friends, or two friends, that I was on the [PEP] drugs, but I was being very discreet about it'' (Int 3).
Here, the participant showed how he withheld his use of PEP from others, intentionally keeping it secret or hidden. He and other respondents were most concerned about how peers might view them for using it.
The unmentionability of PEP among peers also applied to health care staff. A common and unexpected finding was that participants reported being uncomfortable discussing their need for PEP with health care staff. When asked about such experiences, many participants recalled feeling discomfort when they had to answer what many called ''the questions,'' and repeat their reason for seeking PEP. The outcome was that the participants described accessing PEP as unpleasant, not due to invasive testing, but because of the ''questions'' they had to repetitively (re-)answer about the unmentionable. The participants described this when recounting past experiences accessing PEP:
It wasn't a negative experience; it was just getting off work again, longer waits, and having to go through the whole story again. (Int 1) I remember talking to one nurse first. She asked me why I was here. I explained, ''I had unprotected sex and blah blah blah.'' I gave her my story, and that was ok. Then she left and another guy came in and asked me the same questions again. On top of that, he had an intern with him . . . . He asked me all the same questions . . . . I seriously felt like a slut. (Int 3) I was probably awkward because of the things they had to do, like the questions and the details you have to go through. It's awkward. It's not something you want to share, especially people you don't know. (Int 5) Among these participants, even when the process was described as ''fine,'' having to answer ''the questions'' was problematic. Another participant, who used PEP before, recounted how the thought of answering such questions weighed on him before seeking PEP a second time:
I was dreading doing it again, but it wasn't terrible. What exactly do you think you were dreading? The whole process? Yeah, ''here we go again'': another month of pills and then appointments, the questions. (Int 7)
The unmentionability of PEP made the health care providers' history-taking a major negative aspect of seeking PEP. Unsurprisingly, the participants' reasons for not wanting to discuss why they sought PEP with health care providers matched why they did not disclose to peers: anticipated perceptions of stigma.
You never really know if you are being judged or not. I don't know how to explain it. You sometimes feel like, ''well, I don't know the doctor's views on this or if they've been exposed to this, if this is something new for them or not. How are they going to take this? How are they going to respond?'' (Int 2)
As is evident in this quotation, accessing PEP was fraught with anxiety about how health care staff might react. Will they be accepting or stigmatizing? These were concerns voiced by many participants, which contributed to PEP being unmentionable to health care providers, not just to peers. Two participants further reported concerns that their PEP use could be disclosed afterward, specifically, that their health insurance company would share the information: I got medications, and one went through my health insurance plan, which was a bit of a concern . . . .
You just sorta think, ''I don't know what my health insurance does with this information with my employer, if they have to disclose it or what.'' (Int 2)
As can be seen in this quote, the unmentionability of PEP extends beyond verbal discussions and includes how the information could be used more broadly.
Lastly, the location for obtaining PEP affected participants' interpretations of stigma in health care, with preference given to the HIV testing clinic:
When you to go an emergency room, the nurses treat everybody, and they are not particularly educated or knowledgeable about the gay community. Having to listen to a lecture from a nurse after you've already been exposed, even though it was accidental . . . . It was very upsetting when you are already very upset. (Int 1) The nice thing about coming here is that there is no judgment. You go to your doctor, and sometimes you are kind of cautious about what you say. But you come here, and you assume they've heard everything and seen everything, so there's nothing to hide. (Int 2) As these quotations demonstrate, the participants had more favorable comments about the clinical settings they felt were less apt to be judgmental, which decreased the barriers related to PEP being unmentionable.
Dimension 3: Ongoing Sexual Contact
The final dimension of our findings was that, despite perceptions of stigma associated with condomless sex and HIV, which made PEP unmentionable, many participants (putting aside the two who sought PEP after a nonconsensual condom removal) implied that they would probably continue to engage in such sex practices. The feelings of discomfort among our participants thus seemed to be more related to discussing condomless sex than to engaging in it. The following exchange with a participant illustrated this:
I would prefer to have a prescription for it in a preventative way . . . . That would be a better solution than me having a crazy night out, fucking a bunch of guys, and then freaking out about it and going through the whole process.
You're saying it's better to be proactive than reactive? . . . It's embarrassing to come in here. It's embarrassing how stupid the encounter was over the weekend. You have to reveal that sort of information. I think I would prefer the other option by far. (Int 10) In response to the unmentionability surrounding PEP, this participant advocated for PrEP to avoid ''embarrassment'' and ''reveal . . . information'' about his ''stupid . . . encounter.'' Notably, the participant did not report he would change his sexual practices, but wanted PrEP for ''crazy night[s] out.'' Other participants supported this finding that the sexual contact(s) that warranted PEP had previously occurred or would occur again. When asked to explain why they had engaged in condomless sex, participants answered as follows:
It was at the hour of the night of poor decisions. I knew exactly what I was doing . . . Have you had unprotected sex like this before? . . . it did happen. (Int 3) In the heat of the moment, sometimes it changes from protected to unprotected sex. But that is not a foregone conclusion. It's never always to have unprotected sex; it just sometimes happens. (Int 6) I keep saying I hope this is my last time. My sexual habits are changing, so I expect there's less chance that that will happen, but there is still a possibility. (Int 7) After the first experience, I should've learned, right? . . . I would say I am more cautious, but not to say that I may not put myself in that situation again. (Int 12) As depicted in these quotes, the sexual practices that led most of our participants to seek PEP were not isolated. They had occurred previously and would likely reoccur. The unmentionability of PEP thus only prevented disclosure; it did not impede our participants' behavior that led to PEP being warranted in the first place.
Discussion
This study is the first to evaluate subsidized PEP in a nurse-led community setting in Ontario, Canada. Findings from our study demonstrated that participants felt positively about accessing PEP through such services. Although a previous study (Sayer et al., 2009) reported on accessing PEP treatment, our finding regarding the unmentionability of PEP is unique.
Our study had several limitations. First, we had a small sample size (n ¼ 12) of only males who had sex with males from a single city (Ottawa). It is possible that different results would have emerged had we include males with female partners, and female participants, too. Many of these results, therefore, could be an artifact of our sample.
Moreover, our methodology may have influenced our findings. Participants had to agree to an interview, which is known to restrict participation to individuals who are more confident in their opinions. The participants were also describing historical situations, which could affect recall (Coughlin, 1990) . Moreover, we limited our data collection to a single interview per participant. Subsequent interviews with the same person may have yielded different data because the participants may have changed their opinions over time or through the possible reflection incited by the interviews.
Nevertheless, these findings highlight that policymakers must be aware that stigma still applies to PEP and continues to impede health care access (Rueda et al., 2016; Smit et al., 2012) . While unsurprising, this finding adds a nuance to understandings about stigma and HIV prevention; the stigma attached to HIV prevention relates to timing of execution, with those used after the fact being more stigmatized than those used beforehand. This temporal relationship was evident in our results: Although PEP is approximately equal to condoms in HIV prevention effectiveness 1 (CDC, 2016; Weller & Davis-Beaty, 2002) , condoms were the benchmark against which participants compared PEP. This begs the question, if not in relation to HIV prevention, then on what grounds is PEP inferior-and more stigmatized-than condoms?
We feel the answer relates to the fact that the stigma attached to PEP is based on perceptions of responsibility. Specifically, the social expectation is for persons to dutifully engage in rationale decision-making based on the principles of risk avoidance and health maintenance. Those who use PEP fail to enact what Lupton (1995) called the Imperative of Health, which is the social duty to protect and promote health. This undertone was present in our study when the participants described condoms as the ideal of personal and social responsibility. Such an understanding is important for nurses and policymakers because it demonstrates that using medication to prevent HIV transmission is not the issue per se, as evidenced by how PrEP was discussed, and its generally increasing use (Wu et al., 2016) . Rather, the temporal initiation of these medications was key to our participants' statements that PEP, PrEP, and condoms demonstrate varying degrees of social responsibility and self-control. PEP, as unique in this list, is the manifestation of personal failings through exposure to risk.
Castel's (1991) writings on risk explain this point further. As Castel (1991) asserted, preventive interventions become indicative of good risk management, based on the assumption that undesirable behavior may occur and its risk can be mitigated. As Petersen (1997) argued, ''[i]ndividuals whose conduct is deemed contrary to the pursuit of a 'risk-free' existence are likely to be seen, and to see themselves, as lacking self-control, and as therefore, not fulfilling their duties as fully autonomous, responsible citizens' ' (p. 198) . If we apply these principles here, PEP demonstrated a personal failure to make socalled right choices, consequently demonstrating irresponsibility. Whereas condoms and PrEP demonstrate an active will to proactively take responsibility, PEP affirms failed citizenship, making it unmentionable.
The unmentionability surrounding PEP can be further understood using Goffman's (1986) work, which highlighted that inherent within the social conceptualization of stigma is the belief that stigma is proof of past moral failings. An important factor for the bearers of stigma, therefore, relates to whether or not such marks of transgression can be hidden. If masking is possible, individuals can pass as normal (Goffman, 1986) . This is how PEP was described: Participants required PEP because they breached social imperatives of risk aversion; however, because the transgressive behavior was not visible after the fact, the stigma could only be uncovered through disclosure or witnessed behavior. PEP thus became something to keep secret. Understood in this way, Goffman's (1986) work explains why our participants did not want to disclose PEP use and were reluctant to attend clinics where they could be seen accessing services: These were the two main ways by which their stigma became visible. Their goal was, to use Becker's (1963) work in Outsiders, to blend in and not be identified. In the case of PEP, concealment was simple: Do not speak about or be seen accessing PEP.
From such a lens, the participants' reluctance to answer ''the questions'' about why they sought PEP became clearer. To provide this information both breached the protection afforded by nondisclosure and violated the unmentionability of the practices that warranted PEP. That is, answering ''the questions'' exposed one's otherwise hidden personal failures as a dutiful citizen (Petersen, 1997) , and rendered one vulnerable to judgment from peers and health care staff (Goffman, 1986) . From health policy and public health perspectives, however, while keeping this information private protects against stigma, it exposes persons to HIV acquisition. In a similar vein, explorations about HIV nondisclosure have previously examined how the criminal justice system has attempted to overcome this unmentionability by enforcing such disclosure through law; similarly, the outcome has likely been worsening onward HIV transmission, suggesting the need for more explorations on this topic of disclosure and unmentionability (see O 'Byrne, Bryan, & Roy, 2013) .
Policy and Practice Implications
Many of our participants stated that their preference was to access all PEP services in a single location, less to obtain care in one physical place, and more to avoid having to tell their story to multiple providers in diverse settings. These findings suggest that clinicians, administrators, and governmental policymakers should be cognizant that clinical policies require patients to access PEP services in multiple places, may result in patients not accessing care at all. This means that when designing PEP programs, it is important to ensure that clinical and programmatic policies do not impede access. To achieve this, we recommend considering decentralizing, consolidating, and standardizing PEP services.
Decentralization is the process of ensuring that PEP is available in locations where persons who use PEP feel stigma is unlikely to occur, which might mean the relocation of PEP from acute care to primary or community care settings. Following the UNAIDS (2008) strategy of ''Know Your Epidemic,'' this practice change would require health researchers to (a) determine who is most affected by HIV locally, and (b) identify the sites these persons feel would be most conducive to PEP provision. Then, health service policymakers and clinicians should ensure these sites can deliver PEP, which would involve staff training and on-site medication availability. Considerations would also need to ensure that patients can access health care providers in these centers and can afford PEP. This second aspect of decentralization should involve expanding the role of nurses in PEP-a suggestion that this study shows is feasible and supported by patient feedback. Previous research has suggested that such decentralization might also contribute to improved PEP uptake and follow-up (Day, Mears, Bond, & Kulasegaram, 2006) .
Regarding the second item (consolidation), our data highlight that, once researchers have determined the patient-preferred location for PEP delivery, health service policymakers should ensure required services are available at a single site. While in the local context and other jurisdictions, PEP protocols often involve emergency room physicians initiating patients and referring them to infectious disease specialists for follow-up (O 'Byrne et al., 2016; Ende, Hein, Sottolano, & Agins, 2008; Rutland, Sundaram, & Mani, 2010) , our findings suggest that patients prefer to initiate PEP and do follow-up in one place. The implication of this finding is that providers should consider providing the full course of PEP at the first clinical encounter to possibly overcome patients' unwillingness to attend follow-up appointments. By consolidating services, there would be a single patient file that providers could access, which would ideally stop providers from re-asking what our participants described as distressing ''questions'' about why they needed PEP. Consolidating services might reduce the discomfort associated with disclosing why one needs PEP, and might increase the uptake and effectiveness of PEP as a prevention initiative.
As part of such consolidation, health care policies must encourage community providers to initiate PEP and complete required follow-up. That is, policymakers should ensure appropriate remuneration for community providers who dispense PEP and that these providers can order required testing for initiation and follow-up. The latter point is important because, in some jurisdictions or with some insurance providers, certain testing is restricted to specialists or will only be paid in particular clinical scenarios. Policymakers should ensure required testing is funded to allow consolidation of PEP services in community settings. Research from San Francisco and Boston show this is feasible (Kahn et al., 2001; Mayer et al., 2008) .
Third, regarding standardization, our results suggest the utility of clinical pro forma that focuses assessments on the information required for safe PEP provision. This intervention could limit health care providers' extraneous questioning, and align with what our participants reported wanting: The ability to state that they need PEP without having to over-disclose. Even without decentralization and consolidation, this intervention could overcome issues in emergency rooms, such as inconsistencies in assessments and decisions to initiate PEP (Ende et al., 2008; Rutland et al., 2010) . As with consolidation, standardization could minimize some discomfort associated with accessing PEP, and thus potentially improve its utility at the population level.
While the foregoing strategies may seem clinically focused, they are policy modifications about access to care-regarding both cost and clinical environment. We are not advocating for modifications to PEP clinical practices, but for adjustments at the system level regarding affordability and patient preference, including that nurses should be involved in PEP provision. Supporting these policy changes is that communicable disease transmission (HIV in this case) is a population health issue that is transmitted between people, and which often affects marginalized groups, not a health condition that affects single patients one at a time. Ensuring cohesive programs of HIV prevention across the health sectors are accordingly what we recommend. Following Poyten, Smith, Cooper, Kaldor, and Grulich (2007) , the utility of PEP will remain minimal at the population level until it is appropriately offered and targeted as a broader program.
In summary, we feel that decentralizing PEP from tertiary care to community settings would be an appropriate first step, and we encourage policymakers to ensure that funding models incentivize such decentralization. We recommend consolidating services in single environments, and, lastly, we suggest the use of standardized assessment forms that limit ''questions'' to the minimum required to safely provide PEP. We feel that not heeding such recommendations may render efficacious interventions noneffective, and undermine efforts to implement PEP programs in other settings.
Research Implications
A main research implication of this study is the need to determine if our findings are specific to our political, policy, and practice context, or if are they applicable more broadly. Researchers should replicate and evaluate community-based nurse-led PEP provision in other areas with diverse health care funding and access models to establish its functionality and outcomes, and ascertain its HIV prevention utility on an international scale. Another important focus is to compare PEP follow-up by nurses versus infectious disease specialists (as is often the standard-of-care), and determine if nurses can provide this care safely and effectively more generally. At a system level, answering this question could direct policies about how, when, and where patients obtain PEP, which could have implications for cost and physician access. Lastly, as part of evaluating nurse-led PEP, researchers should evaluate the role of other health professionals, including social workers, whose expertise could be utilized to address underlying psychological issues in some patients whose HIV risk behavior may be the manifestation of poor mental health, as has been found in previous research (Tan, Leon-Carlyle, Mills, Moses, & Carvalhal, 2016) .
Conclusion
Although clinicians must obtain information about why patients want PEP (to ensure intervention benefits exceed harms), our participants cited that this clinical process was a barrier. As a recommendation, policymakers should decentralize, consolidate, and standardize PEP services, and address the stigma surrounding PEP. This would streamline services, and have health care providers limit their histories to include only the information required to ensure they safely provide PEP. For our project, it is unknown if or to what extend such disclosures of the unmentionable deterred PEP use, but, that a notable subset of this sample were diagnosed with HIV at later visits after not returning for PEP suggests that this barrier may be pronounced (O 'Byrne, MacPherson, & Orser, 2018) . In these cases, persons may not have sought PEP when they ought to have. Building on this approach, we might maximize the prevention outcomes associated with PEP by decreasing barriers that prevent its use. Diminishing the disclosures required to obtain PEP might be one strategy to accomplish this.
As explained in this article, the ultimate outcome is that the act of accessing PEP was rife with meaning for those who needed it. An overarching narrative of being unmentionable was indicative of an intervention that was interpreted as stigmatized, which, consequently, likely deterred people from accessing needed services. From a health care perspective, the results of this research encourage us to try and consolidate services at the initial point of care to minimize stigmatizing effects of disclosure and encourage increased health services uptake, and decreased overall HIV transmission.
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